|
|
| Enbrel |
All Financial Data in US $ (mln) |
|
Word Search (Top 10 - by date)
|
Vas Narasimhan to Lead Sandoz’ Biosimilars Business
Novartis
(March 27, 2014)
|
Sandoz Receives Approval for Biosimilar Filgrastim in Japan
Novartis
(March 24, 2014)
|
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Pfizer
(March 22, 2014)
|
New Phase III Psoriasis Data Show Rapid, Significant Skin Clearance and Convenient Administration with Novartis' Secukinumab (AIN457)
Novartis
(March 22, 2014)
|
Novartis Announces Start of New Secukinumab (AIN57) Versus Stelara® (ustekinumab) Phase IIIb Head-to-head Psoriasis Study at AAD 2014
Novartis
(March 21, 2014)
|
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
Pivotal Therapeutics
(March 10, 2014)
|
Tekmira Announces New Appointment to Board of Directors
Tekmira Pharmaceuticals
(February 12, 2014)
|
Summary of Financial Statements for the Nine Month Period Ended December 31, 2013 (Japan GAAP, Consolidated)
Takeda
(February 05, 2014)
|
Amgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60
Amgen
(January 28, 2014)
|
Pfizer Reports Fourth-Quarter and Full-Year 2013 Results
Pfizer
(January 28, 2014)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
|
Product Sales Summary 2009/10
|
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2010 |
| Enbrel2 |
|
|
|
7,257 |
|
|
|
|
Clinical Trial Coverage: No. of Trials involving Product
|
|
|
|
Welcome
Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.
Explore Evaluate
Partnering
EvaluatePharma® now includes Partnering Opportunities - products available for licensing.
Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.
Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.
Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.
Register to access more FREE content:
- 2011 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
Register for Free Analysis
Register to access more free insights and analysis from Evaluate.
Register Now
|
|
|
|